estradiol
Trade name: progynon depot
Small moleculeapproved
Approved
Jul 15, 1954
Estradiol 3-sulfate or 17beta-estradiol 3-sulfate is a biologically inactive metabolite of estradiol, which can be converted by steryl sulfatase again to the parent estrogen. — NCATS
Clinical trial activity
489 trials · 346 clinical orgs · 62 marketing orgs
Phase 1
71
Phase 2
204
Phase 3
115
Phase 4
127
Earliest trial started Aug 11, 1992 (NCT00001259)
Timeline
1930s
- Jun 1, 1933
Schering-Plough — First NDA Organization
- Jun 1, 1933
Schering-Plough — NDA Organization
- Feb 13, 1936
Evidence of US Marketing
1950s
- Jul 15, 1954
Earliest FDA Approval
- Jul 15, 1954
Par Pharmaceuticals — NDA Secondary Org
1970s
- Jul 23, 1975
Bristol-Myers Squibb — Marketing Organization
- Feb 28, 1979
Watson Pharmaceuticals — NDA Secondary Org
- Feb 28, 1979
Watson Pharmaceuticals — Marketing Organization
- Feb 28, 1979
Dr. Reddy's Laboratories — Marketing Organization
- Aug 15, 1979
Pharmacia & Upjohn — NDA Secondary Org
1980s
- Jun 29, 1982
Savage Labs — Marketing Organization
- Jan 31, 1984
Allergan — NDA Secondary Org
- Jan 31, 1984
SmithKline Beckman — Marketing Organization
- Sep 10, 1986
Novartis — NDA Secondary Org
1990s
- Jan 1, 1992
Earliest Phase 1 Sponsor(trial)
- Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1994
Novo Nordisk — Earliest Phase 3 Sponsor(trial)
- Oct 28, 1994
Sandoz — Marketing Organization
- Oct 28, 1994
Sandoz — NDA Secondary Org
- Dec 22, 1994
Bayer — NDA Secondary Org
- Mar 14, 1996
Mayne Pharma — Marketing Organization
- Apr 26, 1996
Pfizer — Marketing Organization
- Apr 26, 1996
Pfizer — NDA Secondary Org
- Dec 3, 1996
Parke-Davis — NDA Secondary Org
- Dec 3, 1996
Warner Lambert — NDA Secondary Org
- Dec 20, 1996
SmithKline Beecham — NDA Secondary Org
- Dec 29, 1997
Duramed Research — Marketing Organization
- Jan 30, 1998
Lannett Company, Inc. — Marketing Organization
- Aug 4, 1998
Women First Healthcare — NDA Secondary Org
- Aug 7, 1998
Noven Therapeutics — Marketing Organization
- Nov 18, 1998
Amneal Pharmaceuticals — NDA Secondary Org
- Dec 29, 1998
Epic Pharma Llc — Marketing Organization
- Mar 26, 1999
Novo Nordisk — NDA Secondary Org
- Apr 21, 1999
Mylan — Marketing Organization
- Sep 20, 1999
Johnson and Johnson — NDA Secondary Org
- Oct 22, 1999
Teva — NDA Secondary Org
2000s
- Apr 11, 2000
Novo Nordisk — Marketing Organization
- Oct 5, 2000
Pharmacia — NDA Secondary Org
- Apr 17, 2002
Upsher-Smith Laboratories — Marketing Organization
- Mar 20, 2003
Galen — NDA Secondary Org
- Mar 20, 2003
Warner Chilcott — NDA Secondary Org
- Oct 9, 2003
Exeltis — NDA Secondary Org
- Feb 9, 2004
Stamford Pharmaceuticals — NDA Secondary Org
- Aug 20, 2004
Allergan — Marketing Organization
- Aug 20, 2004
GlaxoSmithKline — NDA Secondary Org
- Apr 29, 2005
Barr Laboratories — Marketing Organization
- Dec 27, 2005
Schering AG — Marketing Organization
- Dec 27, 2005
Schering AG — NDA Secondary Org
- Dec 15, 2006
Mylan — NDA Secondary Org
- Jun 4, 2007
Vertical Pharmaceuticals — NDA Secondary Org
- Jun 4, 2007
Vertical Pharmaceuticals — Marketing Organization
- Jul 27, 2007
Perrigo — NDA Secondary Org
- Jul 27, 2007
Padagis Us — Marketing Organization
- Jul 27, 2007
Padagis Us — NDA Secondary Org
- Oct 4, 2007
Fosun — Marketing Organization
- Apr 17, 2008
Esteve Labs — Marketing Organization
2010s
- Jan 19, 2010
Lutipold — Marketing Organization
- Jan 19, 2010
Sankyo — Marketing Organization
- Jan 19, 2010
Daiichi Sankyo — Marketing Organization
- Mar 8, 2012
Teva — Marketing Organization
- Oct 29, 2012
Noven Therapeutics — NDA Secondary Org
- Oct 29, 2012
Hisamitsu Pharmaceutical Co., Inc. — NDA Secondary Org
- May 29, 2015
Amneal Pharmaceuticals — Marketing Organization
- Jun 20, 2016
Lupin — Marketing Organization
- May 9, 2017
Allergan PLC (2015) — Marketing Organization
- Jan 22, 2018
Perrigo — Marketing Organization
- Feb 28, 2018
Naari Pte Ltd — Marketing Organization
- Feb 28, 2018
Accord Research — Marketing Organization
- Mar 5, 2018
Alvogen — Marketing Organization
- May 29, 2018
TherapeuticsMD — NDA Secondary Org
- May 29, 2018
Mayne Pharma — NDA Secondary Org
- Sep 14, 2018
Glenmark Pharmaceuticals — Marketing Organization
- Apr 3, 2019
Novast Labs — Marketing Organization
2020s
- Apr 21, 2020
Hikma — Marketing Organization
- May 29, 2020
AbbVie — NDA Secondary Org
- May 26, 2021
Myovant Sciences GmbH — NDA Secondary Org
- May 26, 2021
Sumitomo Dainippon — NDA Secondary Org
- Jul 15, 2021
Prasco LLC — Marketing Organization
- Aug 10, 2022
Exeltis — Marketing Organization
- Dec 1, 2022
Zydus Discovery DMCC — Marketing Organization
- Jun 30, 2023
Aurobindo Pharma — Marketing Organization
- Aug 24, 2023
Novitium Pharma — Marketing Organization
Indications
Approved for
Studied for
- Abortion, Spontaneous · Phase 4
- Adenomyosis · Phase 3
- Adiposity · Phase 4
- Aging · Phase 4
- Aging, Premature · Phase 4
- Alzheimer Disease · Phase 2/Phase 3
- Amenorrhea · Phase 2
- Anemia · Phase 3
- Anhedonia · Phase 4
- Anorexia Nervosa · Phase 3
- Anovulation · Phase 4
- Arteriosclerosis · Phase 4
- Asthma · Phase 2
- Ataxia Telangiectasia · Phase 4
- Atherosclerosis · Phase 4
- Atrophic Vaginitis · Phase 4
- Atrophy · Phase 4
- Back Pain · Phase 2
- Blood Coagulation · Early Phase 1
- Body Weight Changes · Phase 4
- Bone Density · Phase 2
- Bone Diseases, Metabolic · Phase 3
- BRCA1 Protein · Phase 2
- Breast Feeding · Phase 4
- Breast Neoplasms · Phase 4
- Bulimia Nervosa · Phase 2
- Burns · Phase 3
- Carcinoma, Lobular · Phase 2
- Cardiovascular Diseases · Phase 4
- Cerebral Arterial Diseases · Early Phase 1
- Cerebral Small Vessel Diseases · Phase 2
- Cesarean Section · Phase 4
- Cicatrix · Phase 2
- Climacteric · Phase 4
- Cognition Disorders · Phase 4
- Cognitive Dysfunction · Phase 2
- Contraception · Phase 4
- Contraception Behavior · Phase 4
- Contraceptive Agents · Phase 2
- Contraceptives, Oral · Phase 3
- Coronary Disease · Phase 3
- COVID-19 · Phase 2
- Cystic Fibrosis · Phase 4
- Cystitis · Phase 4
- Cystitis, Interstitial · Phase 2
- Deficiency Diseases · Phase 4
- Dementia · Phase 1
- Depression · Phase 4
- Depression, Postpartum · Phase 4
- Diabetes Mellitus, Type 1 · Phase 1
- Diabetes Mellitus, Type 2 · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Dry Eye Syndromes · Phase 2
- Dysbiosis · Phase 4
- Dysmenorrhea · Phase 4
- Dyspareunia · Phase 4
- Embryo Transfer · Phase 4
- Emotions · Phase 1
- Endometrial Hyperplasia · Phase 2
- Endometrial Neoplasms · Phase 4
- Endometriosis · Phase 3
- Endometrium · Phase 4
- Endothelial Cells · Phase 2
- Epilepsy · Phase 2
- Estradiol · Phase 2
- Estrogen Replacement Therapy · Phase 4
- Estrogens · Phase 4
- Exercise · Phase 3
- Fatigue Syndrome, Chronic · Phase 2
- Fear · Phase 1/Phase 2
- Fecal Incontinence · Phase 4
- Feeding and Eating Disorders · Phase 2
- Female Urogenital Diseases · Phase 4
- Fertilization in Vitro · Phase 4
- Fibromyalgia · Phase 2
- Gender Dysphoria · Phase 4
- General Surgery · Phase 4
- Genetic Diseases, Inborn · Phase 3
- Growth and Development · Phase 4
- Gynatresia · Phase 2
- Headache · Phase 3
- Healthy Volunteers · Phase 4
- Heart Diseases · Phase 4
- Hemorrhage · Phase 3
- Hemostasis · Phase 1/Phase 2
- HIV · Phase 4
- HIV Infections · Phase 4
- Hormone Replacement Therapy · Phase 4
- Hormones · Phase 4
- Hot Flashes · Phase 4
- Hyperandrogenism · Phase 4
- Hypercalciuria · Phase 2
- Hypertension · Phase 4
- Hyperuricemia · Phase 4
- Hysterectomy · Phase 3
- Infertility · Phase 4
- Infertility, Female · Phase 4
- Infertility, Male · Phase 4
- Insulin Resistance · Phase 4
- Intracranial Aneurysm · Phase 2
- Irritable Bowel Syndrome · Phase 2
- Irritable Mood · Phase 4
- Labor, Obstetric · Phase 2/Phase 3
- Leiomyoma · Phase 4
- Libido · Phase 3
- Lower Urinary Tract Symptoms · Phase 4
- Major Depressive Disorder · Phase 4
- Memory · Phase 1
- Memory Disorders · Phase 4
- Menopause · Phase 4
- Menorrhagia · Phase 4
- Menstruation Disturbances · Phase 4
- Mental Health · Phase 4
- Metabolism · Phase 1/Phase 2
- Metrorrhagia · Phase 4
- Microbiota · Phase 4
- Migraine Disorders · Phase 4
- Multiple Sclerosis · Phase 3
- Muscular Atrophy · Early Phase 1
- Musculoskeletal Diseases · Phase 4
- Mutation · Phase 2
- Myocardial Ischemia · Phase 3
- Neoplasms · Phase 2
- Nocturia · Phase 4
- Non-alcoholic Fatty Liver Disease · Phase 3
- Obesity · Phase 4
- Orthostatic Intolerance · Phase 2
- Osteoporosis · Phase 4
- Ovarian Diseases · Phase 2
- Ovarian Hyperstimulation Syndrome · Phase 4
- Ovarian Reserve · Phase 4
- Ovulation · Phase 4
- Ovulation Inhibition · Phase 4
- Oxytocin · Phase 1
- Pain · Phase 3
- Pelvic Floor Disorders · Phase 4
- Pelvic Organ Prolapse · Phase 4
- Pelvic Pain · Phase 4
- Perimenopause · Phase 4
- Pharmacological and Toxicological Phenomena · Phase 2
- Pharmacology, Clinical · Phase 1
- Polycystic Ovary Syndrome · Phase 4
- Postmenopause · Phase 4
- Pregnancy Complications · Phase 4
- Pregnancy, Unplanned · Phase 2
- Prehypertension · Phase 2
- Premenopause · Phase 4
- Premenstrual Syndrome · Phase 1
- Primary Ovarian Insufficiency · Phase 4
- Progesterone · Phase 4
- Prostatic Neoplasms · Phase 3
- Prostheses and Implants · Phase 4
- Psoriasis · Phase 2
- Psychotic Disorders · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Quality of Life · Phase 4
- Rhinitis, Allergic, Seasonal · Phase 2
- Rotator Cuff Injuries · Phase 2
- Schizophrenia · Phase 3
- Sexual Behavior · Phase 4
- Sexual Dysfunction, Physiological · Phase 4
- Sexual Dysfunctions, Psychological · Phase 4
- Signs and Symptoms · Phase 4
- Sleep Wake Disorders · Phase 4
- Sperm Injections, Intracytoplasmic · Phase 3
- Stress Disorders, Post-Traumatic · Phase 1
- Suicidal Ideation · Phase 4
- Suicide · Phase 2
- Temporomandibular Joint Disorders · Phase 2
- Tension-Type Headache · Phase 2
- Therapeutic Equivalency · Phase 1
- Therapeutics · Phase 2
- Thinness · Phase 4
- Thrombophilia · Phase 4
- Transgender Persons · Phase 4
- Transsexualism · Phase 4
- Turner Syndrome · Phase 4
- Urethral Diseases · Phase 4
- Urinary Bladder, Overactive · Phase 4
- Urinary Incontinence · Phase 4
- Urinary Incontinence, Stress · Phase 4
- Urinary Incontinence, Urge · Phase 4
- Urinary Tract Infections · Phase 4
- Urination Disorders · Phase 4
- Uterine Diseases · Phase 2
- Uterine Hemorrhage · Phase 4
- Vagina · Phase 4
- Vaginal Diseases · Phase 4
- Vaginitis · Phase 4
- Vaginosis, Bacterial · Phase 1
- Varicose Ulcer · Phase 3
- Vascular Diseases · Phase 2
- Vasodilation · Phase 4
- Vasomotor System · Phase 4
- Venous Thrombosis · Phase 4
- Ventricular Dysfunction, Left · Phase 4
- Vulvar Diseases · Phase 3
- Vulvodynia · Phase 2
- White Matter · Phase 2
- Women · Phase 2
- Wound Healing · Phase 2
- Wounds and Injuries · Phase 4
Mechanism of action
- Estrogen receptor alphaAGONIST
ESR1 agonist
Combination products
angeliq
with drospirenone
bijuva
with progesterone
climara pro
with norgestrel
combipatch
with norethindrone
Also known as activella, amabelz
depo-testadiol
with testosterone
Also known as ditate-ds, testosterone cypionate-estradiol cypionate
lunelle
with medroxyprogesterone
myfembree
with relugolix, norethindrone
Also known as relugolix/e2/neta fdc, ryeqo
natazia
with dienogest
oriahnn (copackaged)
with elagolix, norethindrone
prefest
with norgestimate
Approval history
- approvedJul 15, 1954
- approvedFeb 13, 1936
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1CC[C@@H]2O- Mol. weight
- 272.382 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
Yes
Black box warning
Sources
- WikipediaConjugated estrogens/medroxyprogesterone acetate ↗
- NCATS4TI98Z838E ↗
- ChEMBLCHEMBL2356687 ↗
- ChEMBLCHEMBL1697794 ↗
- ChEMBLCHEMBL1697792 ↗
- ChEMBLCHEMBL1697791 ↗
- ChEMBLCHEMBL1611800 ↗
- ChEMBLCHEMBL717 ↗
- ChEMBLCHEMBL135 ↗
- ChEMBLCHEMBL1200973 ↗
- ChEMBLCHEMBL1200430 ↗
- WikipediaEstradiol ↗
- ChEMBLCHEMBL1511 ↗
- ChEMBLCHEMBL282575 ↗
Also known as
- 17 beta-estradiol
- 17 beta-estradiol
- 17-beta estradiol
- 17-beta estradiol
- 17beta-estradiol
- 17beta-estradiol-3-benzoate
- 17 beta-estradiol hemihydrate
- 17beta oestradiol
- 17beta oestradiol
- 17beta-oestradiol
- (17β)-estra-1,3,5(10)-triene-3,17-diol
- (17β)-estra-1,3,5(10)-triene-3,17-diol
- 17β-estra-1,3,5(10)-triene-3,17-diol
- 17β-estra-1,3,5(10)-triene-3,17-diol
- 17β-estradiol
- 17β-estradiol
- 17β-oestradiol
- 17β-oestradiol
- adgyn estro
- agofollin
- agofollin
- alfatradiol
- alfatradiol
- alora
- alora
- aquagen
- bay86-4980
- bay 98-7079
- bedol
- benzestrofol
- benzestrofol
- benzhormovarine
- benzoestrofol
- benzofoline
- benzogynestryl
- benzogynestryl
- benzogynestryl
- benztrone
- benztrone
- beta-estradiol
- beta-estradiol
- beta-estradiol
- beta-estradiol benzoate
- beta-estradiol benzoate
- cis-estradiol
- cis-estradiol
- climara
- climara
- climara pro
- climaval
- climaval
- delestrogen
- delestrogen
- delestrogen
- depo
- depo
- depoestradiol
- depo-estradiol
- depo-estradiol
- depo-estradiol
- depoestradiol cypionate
- dermestril 100
- dermestril 25
- dermestril 50
- dermestril septem 25
- dermestril septem 50
- dermestril septem 75
- destradiol
- destradiol
- difolliculin
- difolliculin
- dihydrotheelin
- dihydrotheelin
- dihydroxyestrin
- dihydroxyestrin
- dimenformon benzoate
- dimenformon dipropionate
- divigel
- divigel
- e3a
- e3a
- e-cypionate
- elestrim
- elestrim
- elestrin
- elestrin
- elleste solo
- elleste solo mx 40
- elleste solo mx 80
- emmenin
- esclim
- esclim
- eston-b
- estrace
- estrace
- estrace
- estraderm
- estraderm
- estraderm mx 100
- estraderm mx 25
- estraderm mx 50
- estraderm mx 75
- estraderm tts 100
- estraderm tts 100
- estraderm tts 25
- estraderm tts 50
- estraderm tts 50
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol
- estradiol-17beta
- estradiol-17beta
- estradiol 17 beta-cyclopentanepropionate
- estradiol 17 beta-cyclopentylpropionate
- estradiol 17 beta-cypionate
- estradiol-3-acetate
- estradiol-3-acetate
- estradiol 3-benzoate
- estradiol acetate
- estradiol acetate
- estradiol acetate
- estradiol acetate
- estradiol acetate
- estradiol acetate
- estradiol acetate
- estradiol benzoate
- estradiol benzoate
- estradiol benzoate
- estradiol benzoate
- estradiol benzoate
- estradiol benzoate
- estradiol benzoate
- estradiol cyclopentylpropionate
- estradiol cypionate
- estradiol cypionate
- estradiol cypionate
- estradiol cypionate
- estradiol cypionate
- estradiol cypionate
- estradiol cypionate
- estradiol cypionate
- estradiol dipropionate
- estradiol dipropionate
- estradiol dipropionate
- estradiol dipropionate
- estradiol dipropionate
- estradiol enanthate
- estradiol enanthate
- estradiol enanthate
- estradiol enanthate
- estradiol enanthate
- estradiol hemihydrate
- estradiol hemihydrate
- estradiol hemihydrate
- estradiol hemihydrate
- estradiol hemihydrate
- estradiol hexahydrobenzoate
- estradiol monobenzoate
- estradiol monobenzoate
- estradiol monobenzoate
- estradiol propionate
- estradiol sulfamate
- estradiol sulfamate
- estradiolum
- estradiolum
- estradiol undecylate
- estradiol undecylate
- estradiol undecylate
- estradiol undecylate
- estradiol undecylate
- estradiol valerate
- estradiol valerate
- estradiol valerate
- estradiol valerate
- estradiol valerate
- estradiol valerate
- estradiol valerate
- estradiol valerate
- estradiol valeriante
- estrasorb
- estrasorb
- estraval
- estring
- estring
- estring
- estrogel
- estrogel
- evamist
- evamist
- evorel 100
- evorel 25
- evorel 50
- evorel 75
- fematrix 40
- fematrix 80
- femogex
- fempatch
- fempatch
- femring
- femring
- femseven 100
- femseven 50
- femseven 75
- femtab
- femtrace
- follidrin
- follidrin
- gvnodiol
- gynergon
- gynergon
- gynodiol
- gynodiol
- gynoestryl
- gynoestryl
- gynogen
- gynogen
- innofem
- innofem
- menorest 37.5
- menorest 50
- menorest 75
- menoring 50
- menostar
- menostar
- minivelle
- minivelle
- neofollin
- nomegestrol acetate / estradiol
- oestradiol
- oestradiol
- oestradiol 3-benzoate
- oestradiol benzoate
- oestradiol benzoate
- oestradiol undecylate
- oestradiol valerate
- oestradiol valerate
- prempro
- prempro
- prempro
- progynon b oleoso
- progynon depot
- progynon depot
- progynon-depot
- progynon-depot-10
- progynova
- progynova
- progynova
- progynova ts
- sandrena
- sandrena
- sh t00658id
- sh t00658id
- vagifem
- vagifem
- vagifem 18
- vagifem 8
- valergen
- vivelle
- vivelle
- vivelle-dot
- vivelle-dot
- wc3011
- zumenon
- zumenon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07212712 | N/A | Mar 1, 2026 | University of British Columbia |
| NCT06856174 | Phase 4 | Jan 19, 2026 | Exeltis, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA) |
| NCT07260825 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2025 | TriHealth |
| NCT07242131 | N/A | Dec 1, 2025 | Ege University |
| NCT07254429 | Phase 2 | Oct 2, 2025 | University of Copenhagen |
| NCT06369363 | Early Phase 1 (Phase 1) | Sep 30, 2025 | Pennsylvania State University |
| NCT07173127 | N/A | Sep 30, 2025 | University of Geneva |
| NCT07041814 | Phase 2 | Jul 15, 2025 | National University of Malaysia |
| NCT07010146 | Phase 2 | Jul 1, 2025 | National Institutes of Health (NIH), University of Virginia |
| NCT06969326 | Phase 3 | May 1, 2025 | Brown University |
| NCT06318403 | Phase 2 | Apr 30, 2025 | University of Utah |
| NCT07160504 | Phase 4 | Mar 21, 2025 | Aarhus University, University of Southern Denmark |
| NCT06798571 | Phase 4 | Mar 1, 2025 | Pennsylvania State University |
| NCT06780163 | Phase 4 | Mar 1, 2025 | Mahidol University |
| NCT06896617 | Phase 4 | Feb 1, 2025 | University of Barcelona |
| NCT06686537 | Phase 4 | Dec 10, 2024 | University of Colorado, University of Colorado, Denver |
| NCT06610305 | Phase 4 | Sep 2, 2024 | National Institute of Mental Health (NIMH), University of North Carolina at Chapel Hill |
| NCT06439524 | Phase 3 | Aug 15, 2024 | Main Line Health, Pfizer |
| NCT06455969 | Phase 4 | Jul 15, 2024 | United States Army, University of Pittsburgh |
| NCT06461039 | Phase 1 | Jun 14, 2024 | Novo Nordisk |
Showing 20 of 489 trials
Page 1 / 25
Organizations
Research & Development (346)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 34 | 32 | 5 | 2002 |
| National Institute of Mental Health (NIMH) | Government | 19 | 5 | 5 | 1992 |
| Harvard University | Academic/Hospital | 18 | 14 | 4 | 2000 |
| Merck | For profit | 18 | 17 | 5 | 2002 |
| Novo Nordisk | For profit | 16 | 13 | 3 | 1994 |
| National Institute on Aging (NIA) | Government | 15 | 1 | 5 | 1994 |
| National Institutes of Health (NIH) | Government | 14 | 1 | 5 | 2005 |
| University of Colorado, Denver | Academic/Hospital | 12 | 12 | 4 | 2007 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 10 | 10 | 4 | 2010 |
| Mayo Clinic | Academic/Hospital | 9 | 7 | 5 | 2005 |
| Capital Medical University | Academic/Hospital | 8 | 8 | 2 | 2013 |
| Myovant Sciences GmbH | For profit | 8 | 7 | 3 | 2017 |
| University of Washington | Academic/Hospital | 8 | 5 | 3 | 1998 |
| AbbVie | For profit | 7 | 7 | 2 | 2011 |
| Johnson and Johnson | For profit | 7 | 7 | 3 | 1997 |
| Cairo University | Academic/Hospital | 6 | 6 | 4 | 2013 |
| National Cancer Institute (NCI) | Government | 6 | 0 | 2 | 2004 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 6 | 2 | 5 | 1995 |
| University of Copenhagen | Academic/Hospital | 6 | 5 | 2 | 2005 |
| Warner Chilcott | For profit | 6 | 6 | 2 | 2003 |
346 organizations
Page 1 / 18
Marketing (93)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | NDA2 | May 29, 2020 |
| Accord Research | For profit | MKTG | Feb 28, 2018 |
| Allergan | For profit | NDA2 | Jan 31, 1984 |
| Allergan | For profit | MKTG | Aug 20, 2004 |
| Allergan | For profit | SYN | Jan 31, 1984 |
| Allergan PLC (2015) | For profit | MKTG | May 9, 2017 |
| Alvogen | For profit | MKTG | Mar 5, 2018 |
| Alvogen | For profit | MKTG | Mar 5, 2018 |
| Amneal Pharmaceuticals | For profit | NDA2 | Nov 18, 1998 |
| Amneal Pharmaceuticals | For profit | MKTG | May 29, 2015 |
| Amneal Pharmaceuticals | For profit | SYN | Nov 18, 1998 |
| Athenex, Inc. | For profit | MKTG | — |
| Aurobindo Pharma | For profit | MKTG | Jun 30, 2023 |
| Barr Laboratories | For profit | MKTG | Apr 29, 2005 |
| Barr Laboratories | For profit | SYN | Oct 22, 1997 |
| Bayer | For profit | NDA2 | Dec 22, 1994 |
| Bristol-Myers Squibb | For profit | MKTG | Jul 23, 1975 |
| Daiichi Sankyo | For profit | MKTG | Jan 19, 2010 |
| Dr. Reddy's Laboratories | For profit | MKTG | Feb 28, 1979 |
| Dr. Reddy's Laboratories | For profit | SYN | Mar 14, 1996 |
| Duramed Research | For profit | MKTG | Dec 29, 1997 |
| Epic Pharma Llc | For profit | SYN | Dec 29, 1998 |
| Epic Pharma Llc | For profit | MKTG | Dec 29, 1998 |
| Epic Pharma Llc | For profit | SYN | Dec 29, 1998 |
| Esteve Labs | For profit | MKTG | Apr 17, 2008 |
| Exeltis | For profit | MKTG | Aug 10, 2022 |
| Exeltis | For profit | NDA2 | Oct 9, 2003 |
| Exeltis | For profit | SYN | Apr 28, 2023 |
| Fosun | For profit | MKTG | Oct 4, 2007 |
| Galen | For profit | NDA2 | Mar 20, 2003 |
| GlaxoSmithKline | For profit | NDA2 | Aug 20, 2004 |
| Glenmark Pharmaceuticals | For profit | MKTG | Sep 14, 2018 |
| Hikma | For profit | MKTG | Apr 21, 2020 |
| Hisamitsu Pharmaceutical Co., Inc. | For profit | NDA2 | Oct 29, 2012 |
| Johnson and Johnson | For profit | NDA2 | Sep 20, 1999 |
| Lannett Company, Inc. | For profit | SYN | Jan 30, 1998 |
| Lannett Company, Inc. | For profit | MKTG | Jan 30, 1998 |
| Lupin | For profit | MKTG | Jun 20, 2016 |
| Lutipold | For profit | MKTG | Jan 19, 2010 |
| Mayne Pharma | For profit | MKTG | Mar 14, 1996 |
| Mayne Pharma | For profit | NDA2 | May 29, 2018 |
| Mylan | For profit | NDA2 | Dec 15, 2006 |
| Mylan | For profit | MKTG | Apr 21, 1999 |
| Mylan | For profit | SYN | Feb 10, 2017 |
| Mylan | For profit | SYN | Dec 19, 2014 |
| Mylan | For profit | SYN | Feb 24, 2000 |
| Myovant Sciences GmbH | For profit | NDA2 | May 26, 2021 |
| Naari Pte Ltd | For profit | MKTG | Feb 28, 2018 |
| Novartis | For profit | NDA2 | Sep 10, 1986 |
| Novast Labs | For profit | MKTG | Apr 3, 2019 |
| Noven Therapeutics | For profit | NDA2 | Oct 29, 2012 |
| Noven Therapeutics | For profit | MKTG | Aug 7, 1998 |
| Novitium Pharma | For profit | MKTG | Aug 24, 2023 |
| Novo Nordisk | For profit | NDA2 | Mar 26, 1999 |
| Novo Nordisk | For profit | MKTG | Apr 11, 2000 |
| Padagis Us | For profit | MKTG | Jan 22, 2018 |
| Padagis Us | For profit | MKTG | Jul 27, 2007 |
| Padagis Us | For profit | NDA2 | Jul 27, 2007 |
| Par Pharmaceuticals | For profit | NDA2 | Jul 15, 1954 |
| Parke-Davis | For profit | NDA2 | Dec 3, 1996 |
| Perrigo | For profit | NDA2 | Jul 27, 2007 |
| Perrigo | For profit | MKTG | Jan 22, 2018 |
| Pfizer | For profit | MKTG | Apr 26, 1996 |
| Pfizer | For profit | NDA2 | Apr 26, 1996 |
| Pharmacia | For profit | NDA2 | Oct 5, 2000 |
| Pharmacia & Upjohn | For profit | NDA2 | Aug 15, 1979 |
| Prasco LLC | For profit | MKTG | Jul 15, 2021 |
| Prasco LLC | For profit | SYN | Jul 15, 2021 |
| Sandoz | For profit | MKTG | Oct 28, 1994 |
| Sandoz | For profit | NDA2 | Oct 28, 1994 |
| Sankyo | For profit | MKTG | Jan 19, 2010 |
| Savage Labs | For profit | MKTG | Jun 29, 1982 |
| Schering AG | For profit | MKTG | Dec 27, 2005 |
| Schering AG | For profit | NDA2 | Dec 27, 2005 |
| Schering-Plough | For profit | NDA | Jun 1, 1933 |
| SmithKline Beckman | For profit | MKTG | Jan 31, 1984 |
| SmithKline Beecham | For profit | NDA2 | Dec 20, 1996 |
| Stamford Pharmaceuticals | For profit | NDA2 | Feb 9, 2004 |
| Sumitomo Dainippon | For profit | NDA2 | May 26, 2021 |
| Teva | For profit | MKTG | Mar 8, 2012 |
| Teva | For profit | SYN | Oct 22, 1999 |
| Teva | For profit | NDA2 | Oct 22, 1999 |
| TherapeuticsMD | For profit | NDA2 | May 29, 2018 |
| Upsher-Smith Laboratories | For profit | MKTG | Apr 17, 2002 |
| Vertical Pharmaceuticals | For profit | NDA2 | Jun 4, 2007 |
| Vertical Pharmaceuticals | For profit | MKTG | Jun 4, 2007 |
| Warner Chilcott | For profit | NDA2 | Mar 20, 2003 |
| Warner Lambert | For profit | NDA2 | Dec 3, 1996 |
| Watson Pharmaceuticals | For profit | NDA2 | Feb 28, 1979 |
| Watson Pharmaceuticals | For profit | MKTG | Feb 28, 1979 |
| Women First Healthcare | Academic/Hospital | NDA2 | Aug 4, 1998 |
| Zydus Discovery DMCC | For profit | MKTG | Dec 1, 2022 |
| Zydus Discovery DMCC | For profit | SYN | Dec 1, 2022 |